SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a… Read more
SCHOTT Pharma AG & Co. KGaA (1SXP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: 0.096x
Based on the latest financial reports, SCHOTT Pharma AG & Co. KGaA (1SXP) has a cash flow conversion efficiency ratio of 0.096x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€75.97 Million) by net assets (€792.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SCHOTT Pharma AG & Co. KGaA - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SCHOTT Pharma AG & Co. KGaA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SCHOTT Pharma AG & Co. KGaA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
COFCO Joycome Foods Limited
F:0M7
|
0.049x |
|
Shenzhen WOTE Advanced Materials Co Ltd
SHE:002886
|
0.017x |
|
Wowprime Corp
TW:2727
|
0.160x |
|
Obsidian Energy Ltd
NYSE MKT:OBE
|
0.032x |
|
TOYO ENGINEERG-6330-
F:6AE
|
N/A |
|
Lee and Man Paper Manufacturing Limited
F:LMP
|
0.029x |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
0.019x |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
|
-0.021x |
Annual Cash Flow Conversion Efficiency for SCHOTT Pharma AG & Co. KGaA (2020–2024)
The table below shows the annual cash flow conversion efficiency of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | €792.27 Million | €225.33 Million | 0.284x | +8.37% |
| 2023-06-30 | €692.18 Million | €181.65 Million | 0.262x | +2.17% |
| 2022-06-30 | €709.04 Million | €182.12 Million | 0.257x | -18.52% |
| 2021-06-30 | €419.42 Million | €132.21 Million | 0.315x | -4.69% |
| 2020-06-30 | €315.66 Million | €104.40 Million | 0.331x | -- |